Lilly(US:LLY) Zhi Tong Cai Jing·2025-12-10 02:14Group 1 - Eli Lilly announced a $6 billion investment to build a manufacturing facility in Huntsville, Alabama, aimed at increasing production capacity for its experimental oral weight loss drug and other medications [1] - This facility marks the third investment in a series of new U.S. facilities, following a previous announcement in February regarding a $27 billion investment to build four domestic manufacturing plants, adding to the $23 billion already invested since 2020 [1] - The Alabama facility is expected to begin construction in 2026 and be completed by 2032, enhancing supply chain resilience and ensuring reliable access to medications for U.S. patients [1] Group 2 - The new plant will create 450 jobs in the local area, including positions for engineers, scientists, operations staff, and laboratory technicians, along with 3,000 construction jobs [2] - Eli Lilly has recently lowered the price of its weight loss drug Zepbound, with the lowest dose now costing $299 per month, a reduction of about $50, while the second-highest dose will be priced at $399, down approximately $20 [2] - Eli Lilly, Pfizer, and Johnson & Johnson have secured a place in China's first innovative drug catalog, opening new market channels and enhancing sales prospects for expensive advanced therapies [2]